Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1292-1300

  Dawar, Swati ^a   Singh, Neha ^a   Kanwar, Rupinder K ^a   Kennedy, Richard Lee ^a   Veedu, Rakesh N ^b   Zhou, Shu Feng ^c   Krishnakumar, Subramanian ^d   Hazra, Sarbani ^e   Sasidharan, Sreenivasan ^f   Duan, Wei ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VISION RESEARCH FOUNDATION   (India)

^e WEST BENGAL UNIVERSITY OF ANIMAL AND FISHERY SCIENCES   (India)

^f INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTINEOPLASTIC AGENT; APTAMER; AS 1411; CALCIUM PHOSPHATE; CAMPTOTHECIN DERIVATIVE; CHITOSAN; CONATUMUMAB; DENDRIMER; EGAPTIVON PEGOL; GOLD NANOPARTICLE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IBRITUMOMAB TIUXETAN; IRON DEXTRAN; LACTOFERRIN; LIPOSOME; MACROGOL; MAGNETITE NANOPARTICLE; NANOCARRIER; NANOPARTICLE; NANOSHELL; NANOTUBE; PACLITAXEL; PEGAPTANIB; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; PROTEIN P53; SILVER NANOPARTICLE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURVIVIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; HUMAN; HYDROGEL; LIPOSOMAL DELIVERY; METASTASIS; NANOTECHNOLOGY; REVIEW; DRUG DESIGN; DRUG RESISTANCE; NEOPLASMS; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

EID: 84889092142     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.09.009     Document Type: Review

References (80)

1. C. Leaf Why we're losing the war on cancer (and how to win it) Fortune 149 2004 76 82 84-86, 88
2. X.J. Liang Circumventing tumor resistance to chemotherapy by nanotechnology Methods Mol. Biol. 596 2010 467 488
3. A.L. Harris, and D. Hochhauser Mechanisms of multidrug resistance in cancer treatment Acta Oncol. 31 2 1992 205 213
4. Y.A. Luqmani Mechanisms of drug resistance in cancer chemotherapy Med. Princ. Pract. 14 Suppl. 1 2005 35 48
5. M. Links, and R. Brown Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs Expert Rev. Mol. Med. 1999 1999 1 21
6. H. Goossens Outpatient antibiotic use in Europe and association with resistance: a cross-national database study Lancet 365 2005 579 587
7. J.R. Kanwar Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma Nanomedicine 6 2011 701 714
8. J.R. Kanwar MicroRNA in human cancer and chronic inflammatory diseases Front. Biosci. S2 2010 1113 1126
9. J.R. Kanwar Chimeric aptamers in cancer cell-targeted drug delivery Crit. Rev. Biochem. Mol. Biol. 46 2011 459 477
10. L. Brannon-Peppas, and J.O. Blanchette Nanoparticle and targeted systems for cancer therapy Adv. Drug Deliv. Rev. 56 2004 1649 1659
11. I. Brigger Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651
12. J. Kanwar Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases Nanomedicine 5 2010 1435 1445
13. S. Bosi Antimycobacterial activity of ionic fullerene derivatives Bioorg. Med. Chem. Lett. 10 2000 1043 1045
14. M. Wang Nanotechnology for targeted cancer therapy Expert Rev. Anticancer Ther. 7 2007 833 837
15. M. Melancon Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer Biomaterials 32 2011 7600 7608
16. Y. Geng Shape effects of filaments versus spherical particles in flow and drug delivery Nat. Nanotechnol. 2 2007 249 255
17. D. Lasic Novel applications of liposomes Trends Biotechnol. 16 1998 307 321
18. J. Kanwar Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy Nanomedicine 2012 10.2217/NNM.12.29
19. L.S. Jabr-Milane Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat Rev. 34 7 2008 579 602
20. A. Fotoohi, and F. Albertioni Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells Leuk. Lymph. 49 2008 410 426
21. M. Das Ligand-based targeted therapy for cancer tissue Expert Opin. Drug Deliv. 6 2009 285 304
22. M. Talekar Targeting of nanoparticles in cancer: drug delivery and diagnostics Anticancer Drugs 22 2011 949 962
23. F. De Angelis Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context Nanoscale 2 2010 2230 2236
24. K. Derakhshandeh Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients Int. J. Nanomed. 5 2010 463 471
25. J.J. Yin Synthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatment PLoS ONE 8 2013 e62289
26. S. Dhar Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U. S. A. 105 2008 17356 17361
27. R. Dinarvand Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomed. 6 2011 877 895
28. L. Pan Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer J. Cancer Res. Clin. Oncol. 137 2011 19 28
29. J.R. Kanwar 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy Immunol. Cell. Biol. 86 2008 277 288
30. J. Xie PET/NIRF/MRI triple functional iron oxide nanoparticles Biomaterials 31 2010 3016 3022
31. N. Jo Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization Am. J. Pathol. 168 2006 2036 2053
32. R.C. Becker, and M.Y. Chan REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis Curr. Opin. Mol. Ther. 11 2009 707 715
33. M. Freedman Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases Acad. Radiol. 16 2009 627 637
34. J. Ding Uptake of monostearin solid lipid nanoparticles by A549 cells Acta Pharm. Sin. 39 2004 876 880
35. B. Book Newell Multifunctional gold nanorod theragnostics probed by multi-photon imaging Eur. J. Med. Chem. 48 2012 330 337
36. R. Kanwar Recent advances in anti-survivin treatments for cancer Curr. Med. Chem. 17 2010 1509 1515
37. J.R. Kanwar Targeting survivin in cancer: the cell-signalling perspective Drug Discov. Today 16 2011 485 494
38. J.R. Kanwar Survivin signaling in clinical oncology: a multifaceted dragon Med Res Rev 33 4 2013 765 789
39. G. Kasof, and B. Gomes Livin, a novel inhibitor of apoptosis protein family member J. Biol. Chem. 276 2001 3238 3246
40. J. Plati Apoptotic cell signaling in cancer progression and therapy Integr. Biol. 3 2011 279 296
41. C. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell. Biol. 8 1992 67 113
42. L. Goldstein Expression of a multidrug resistance gene in human cancers J. Natl. Cancer Inst. 81 1989 116 124
43. K. Bogman HMG-CoA reductase inhibitors and P-glycoprotein modulation Br. J. Pharmacol. 132 2001 1183 1192
44. C. Lee HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter Biochemistry 37 1998 3594 3601
45. M. Ramachandra Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state Biochemistry 37 1998 5010 5019
46. Z. Sauna, and S. Ambudkar Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein Proc. Natl. Acad. Sci. U. S. A. 97 2000 2220 2515
47. C.H. Lee Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR) Curr. Med. Chem. Anticancer Agents 4 2004 43 52
48. C. Calatozzolo Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma J. Neurooncol. 74 2005 113 121
49. M. Kuo The roles of copper transporters in cisplatin resistance Cancer Metast. Rev. 261 2007 71 83
50. T. Ishikawa The ATP-dependent glutathione S-conjugate export pump Trends Biochem. Sci. 17 1992 463 468
51. G. Balendiran The role of glutathione in cancer Cell. Biochem. Funct. 22 2004 343 352
52. S. Kizaka-Kondoh Tumor hypoxia: a target for selective cancer therapy Cancer Sci. 94 2003 1021 1028
53. X. Sun Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha Gene Ther. 10 2003 2081 2089
54. H. Deng Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells J. Biol. Chem. 277 2002 15035 15043
55. M. Gottesman Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
56. H. Burger Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines Int. J. Cancer 81 1999 620 628
57. S. Prabha, and V. Labhasetwar Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells Mol. Pharm. 1 2004 211 219
58. Y. Patil The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials 31 2010 358 365
59. D. Kim Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH Small 4 2008 2043 2050
60. Y. Chen Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 285 2010 22639 22650
61. L. Etgar Optical and magnetic properties of conjugate structures of PbSe quantum dots and gamma-Fe(2)O(3) nanoparticles Chemphyschem 10 2009 2235 2241
62. L. Fu Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother. Pharmacol. 53 2004 349 356
63. A. Chen Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small 5 2009 2673 2677
64. n nanoparticles in tumor-bearing mice Biochem. Pharmacol. 71 2006 872 881
65. J.R. Kanwar Targeting survivin in cancer: patent review Expert Opin. Ther. Patents 20 2010 1723 1737
66. B. Pan Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system Cancer Res. 67 2007 8156 8163
67. G. Bartholomeusz In vivo therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1) using single-walled carbon nanotubes noncovalently coated with siRNA Nano Res. 2 2009 279 291
68. H. Devalapally Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model Cancer Chemother. Pharmacol. 59 2007 477 484
69. D. Shenoy Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies Pharm. Res. 22 2005 2107 2114
70. E. Lee Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor J. Control Release 103 2005 405 418
71. R. Kanwar Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come? Nanomedicine 7 2012 899 916
72. L. Cruz Multimodal imaging of nanovaccine carriers targeted to human dendritic cells Mol. Pharm. 8 2011 520 531
73. L.E. Vlerken, and M.M. Amitji Multi-functional polymeric nanoparticles for tumour-targeted drug delivery Expert Opin. Drug Deliv. 3 2006 205 216
74. Y.B. Patil The use of nanoparticle-mediated targted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials 31 2010 358 365
75. H. Meng Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line ACS Nano 4 2010 4539 4550
76. V.S. Swamy, and R. Prasad Green synthesis of silver nanoparticles from the leaf extract of Santalum album and its antimicrobial activity J. Optoelect. Biomed. Mater. 4 2012 53 59
77. L. Yang Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging Small 5 2008 235 243
78. J.F. Kukowska-Latallo Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer Cancer Res. 65 2005 5317 5324
79. T.-J. Chen Targeted herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI J. Biol. Inorg. Chem. 14 2009 253 260
80. S. Dhara Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U. S. A. 105 2008 17356 17361